Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics, Inc.

阿里云企航提供域名产品、网站建设、商标软著、资质备案、案例库和移动端服务。

阿里云企航

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Eterna Therapeutics Inc.

Immunome is a clinical-stage targeted oncology company focused on developing targeted therapies to improve outcomes for cancer patients. The company has an innovative portfolio of therapeutics, including antibody-drug conjugates and treatments for desmoid tumors.

Immunome

Protagonist Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing peptide drug therapies targeting areas of unmet need across rare and prevalent diseases.

Metric
Company Name	Protagonist Therapeutics, Inc.	阿里云企航	Eterna Therapeutics Inc.	Immunome
Symbol	PTGX		ERNA
MSH ID	COM:PROTAGONIST-INC	COM:DACBIOTECH	COM:ETERNATX	COM:IMMUNOME
Market	STOCKS	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare	Technology	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Cloud Computing and Internet Services	Biotechnology	Pharmaceuticals
Country	US	CN	US	US
Stage	Post-IPO Equity
Employee Count	124		8
Website	protagonist-inc.com	dacbiotech.com	brooklynitx.com	immunome.com
LinkedIn				immunome-inc-
Founders

Metric
Market Cap	2.04B	9.90M
Enterprise Value
Monthly Web Traffic	3.14K	270.57K
Web Traffic Growth	0.28	0.55
Valuation
Raised Capital	132.20M

Metric
Revenue	60M	68K
Revenue (LTM)
Revenue (NTM)
Gross Profit	56.69M	-1.29M
EBITDA	-90.34M	-19.55M
Operating Income	-93.65M	-20.67M
Net Income	-78.95M	-21.67M
EPS	-1.39	-4.08
Diluted EPS	-1.39	-4.08
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.99	-5.88
Operating Profit Margin	0.48	-135.73
EBITDA Margin	-1.51	-287.51
Net Profit Margin	0.53	-147.65
Return on Equity	1.18	15.58
Return on Assets	0.28	-0.44
Return on Capital Employed	0.27	-0.50

COM:PROTAGONIST-INC

Protagonist Therapeutics Inc.

Last Close

41.65

22/11 21:00

Market Cap

2.04B

Beta: -

Volume Today

1.32M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-11.44	-0.42
P/B Ratio	-2.41	2.34
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	27.34	192.73
EV Multiple	20.49	2.09

Metric
Days Sales Outstanding		12.71K
Days Payables Outstanding		4.45K
Days Inventory Outstanding	0.00
Operating Cycle	348.14	2.28K
Cash Conversion Cycle	-22.23	1.79K
Asset Turnover	0.52	0.00

Metric
Operating Cash Flow	-70.24M	-20.41M
Free Cash Flow	-70.84M	-20.43M
Cash Flow to Debt	17.00	-0.38
Operating Cash Flow/Sales	0.73	-101.81
Free Cash Flow Yield	-0.08	-2.54

Metric
Cash & Equivalents	186.73M	7.58M
Accounts Receivable	-9.99M	527K
Inventory	-10.33M
Goodwill		2.04M
Debt to Capitalization	0.02	2.84
Debt to Assets	0.01	0.79
Current Ratio	11.66	0.73
Quick Ratio	16.54	1.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			28.90
R&D to Revenue			130.82
SG&A to Revenue			252.08